PLAVIX 300 MG

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

CLOPIDOGREL AS HYDROGEN SULFATE 300 MG

Commercializzato da:

SANOFI - AVENTIS ISRAEL LTD

Codice ATC:

B01AC04

Forma farmaceutica:

FILM COATED TABLETS

Via di somministrazione:

PER OS

Prodotto da:

SANOFI WINTHROP INDUSTRIE, FRANCE

Gruppo terapeutico:

CLOPIDOGREL

Indicazioni terapeutiche:

Prevention of atherotrobmotic eventsClopidogrel is indicated in :• Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• Adult Patients suffering from Acute Coronary Syndrome- Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapyPrevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopid

Data dell'autorizzazione:

2013-09-01